Home LiteratureArticle Details
PMID: 10639353 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds.

Antimicrobial agents and chemotherapy ·Vol. 44 ·No. 2 ·2000-02-00 ·Pages 294-303

Pfeltz RF, Singh VK, Schmidt JL, Batten MA, Baranyk CS, Nadakavukaren MJ, Jayaswal RK, Wilkinson BJ

Abstract

A series of 12 Staphylococcus aureus strains of various genetic backgrounds, methicillin resistance levels, and autolytic activities were subjected to selection for the glycopeptide-intermediate S. aureus (GISA) susceptibility phenotype on increasing concentrations of vancomycin. Six strains acquired the phenotype rapidly, two did so slowly, and four failed to do so. The vancomycin MICs for the GISA strains ranged from 4 to 16 microg/ml, were stable to 20 nonselective passages, and expressed resistance homogeneously. Neither ease of acquisition of the GISA phenotype nor the MIC attained correlated with methicillin resistance hetero- versus homogeneity or autolytic deficiency or sufficiency. Oxacillin MICs were generally unchanged between parent and GISA strains, although the mec members of both isogenic methicillin-susceptible and methicillin-resistant pairs acquired the GISA phenotype more rapidly and to higher MICs than did their susceptible counterparts. Transmission electron microscopy revealed that the GISA strains appeared normal in the absence of vancomycin but had thickened and diffuse cell walls when grown with vancomycin at one-half the MIC. Common features among GISAs were reduced doubling times, decreased lysostaphin susceptibilities, and reduced whole-cell and zymographic autolytic activities in the absence of vancomycin. This, with surface hydrophobicity differences, indicated that even in the absence of vancomycin the GISA cell walls differed from those of the parents. Autolytic activities were further reduced by the inclusion of vancomycin in whole-cell and zymographic studies. The six least vancomycin-susceptible GISA strains exhibited an increased capacity to remove vancomycin from the medium versus their parent lines. This study suggests that while some elements of the GISA phenotype are strain specific, many are common to the phenotype although their expression is influenced by genetic background. GISA strains with similar glycopeptide MICs may express individual components of the phenotype to different extents.

MeSH Terms
Anti-Bacterial Agents/pharmacology Antigens, Surface Bacteriolysis Cell Wall/drug effects,ultrastructure Culture Media Humans Lysostaphin/pharmacology Microbial Sensitivity Tests Mutation Phenotype Staphylococcus aureus/drug effects,growth & development Vancomycin/pharmacology Vancomycin Resistance/genetics,physiology
Chemicals
Anti-Bacterial Agents Antigens, Surface Culture Media Vancomycin Lysostaphin
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Pfeltz R F
Microbiology Group, Department of Biological Sciences, Illinois State University, Normal, Illinois 61790-4120, USA.
Singh V K
Schmidt J L
Batten M A
Baranyk C S
Nadakavukaren M J
Jayaswal R K
Wilkinson B J
References (32)
32 references, click to expand
  1. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.
    J Bacteriol. 1997 Apr;179(8):2557-66 PMID: 9098053
  2. Molecular aspects of methicillin resistance in Staphylococcus aureus.
    J Antimicrob Chemother. 1994 Jan;33(1):7-24 PMID: 8157576
  3. In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin.
    Antimicrob Agents Chemother. 1986 Nov;30(5):813-5 PMID: 2948444
  4. Resistance of Staphylococcus aureus to penicillins and cephalosporins: reversal of intrinsic resistance with some chelating agents.
    Ann N Y Acad Sci. 1974 Jul 31;236(0):435-43 PMID: 4214383
  5. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species.
    J Antimicrob Chemother. 1991 Jan;27(1):71-9 PMID: 1828799
  6. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
    J Antimicrob Chemother. 1997 Jul;40(1):135-6 PMID: 9249217
  7. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50.
    J Antimicrob Chemother. 1998 Sep;42(3):315-20 PMID: 9786471
  8. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.
    Lancet. 1997 Dec 6;350(9092):1670-3 PMID: 9400512
  9. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.
    J Clin Microbiol. 1998 Apr;36(4):1020-7 PMID: 9542929
  10. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus.
    FEMS Microbiol Lett. 1992 Jun 1;72(2):195-8 PMID: 1505742
  11. Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996.
    MMWR Morb Mortal Wkly Rep. 1997 Jul 11;46(27):624-6 PMID: 9218648
  12. Vancomycin resistance in staphylococci.
    Drug Resist Updat. 1998;1(2):135-50 PMID: 16904400
  13. Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures.
    Am J Med. 1991 Sep 16;91(3B):221S-227S PMID: 1928168
  14. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis.
    J Infect Dis. 1990 Jul;162(1):103-8 PMID: 2141343
  15. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.
    J Antimicrob Chemother. 1998 Aug;42(2):199-209 PMID: 9738837
  16. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility.
    J Infect Dis. 1992 Nov;166(5):1066-72 PMID: 1402017
  17. Vancomycin-resistant staphylococcus.
    N Engl J Med. 1987 Sep 17;317(12):766-8 PMID: 3627189
  18. Autolysis of methicillin-resistant and -susceptible Staphylococcus aureus.
    Antimicrob Agents Chemother. 1992 Mar;36(3):566-72 PMID: 1320363
  19. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.
    N Engl J Med. 1999 Feb 18;340(7):517-23 PMID: 10021472
  20. Molecular cloning, sequencing, and expression of lytM, a unique autolytic gene of Staphylococcus aureus.
    J Bacteriol. 1997 Jun;179(11):3625-31 PMID: 9171409
  21. Suppression of glycopeptide resistance in a highly teicoplanin-resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell wall synthesis.
    Microb Drug Resist. 1998 Fall;4(3):159-68 PMID: 9818967
  22. Hydrophobicity-hydrophilicity of staphylococci.
    J Med Microbiol. 1987 Aug;24(1):65-73 PMID: 3112399
  23. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus.
    Antimicrob Agents Chemother. 1997 Aug;41(8):1788-93 PMID: 9257762
  24. A Staphylococcus aureus autolysin that has an N-acetylmuramoyl-L-alanine amidase domain and an endo-beta-N-acetylglucosaminidase domain: cloning, sequence analysis, and characterization.
    Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):285-9 PMID: 7816834
  25. Autolysis-defective mutant of Staphylococcus aureus: pathological considerations, genetic mapping, and electron microscopic studies.
    Infect Immun. 1994 Apr;62(4):1406-9 PMID: 7907580
  26. Intrinsic resistance to beta-lactam antibiotics in Staphylococcus aureus.
    FEBS Lett. 1980 Dec 29;122(2):275-8 PMID: 7202719
  27. Isolation and characterization of autolysis-defective mutants of Staphylococcus aureus created by Tn917-lacZ mutagenesis.
    J Bacteriol. 1993 Mar;175(5):1493-9 PMID: 8095258
  28. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia.
    Emerg Infect Dis. 1999 Jan-Feb;5(1):147-9 PMID: 10081683
  29. In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin.
    J Antimicrob Chemother. 1998 Oct;42(4):552-3 PMID: 9818762
  30. Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    MMWR Morb Mortal Wkly Rep. 1997 Sep 5;46(35):813-5 PMID: 9310213
  31. Molecular characterization and functional analysis of the major autolysin of Staphylococcus aureus 8325/4.
    J Bacteriol. 1995 Oct;177(19):5723-5 PMID: 7559367
  32. Presence of UDP-N-acetylmuramyl-hexapeptides and -heptapeptides in enterococci and staphylococci after treatment with ramoplanin, tunicamycin, or vancomycin.
    J Bacteriol. 1997 Aug;179(15):4684-8 PMID: 9244253
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
2000-02-00
Pages
294-303
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC89674
Subset
IM
Grants
NIAID NIH HHS · 1 R15 AI43027-01 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]